Clinical Research

Construction and validation of a risk prediction model for clinical characteristics of patients with chronic non⁃bacterial prostatitis

  • Yuhai QIAO ,
  • Chunhua DU ,
  • Xinhong ZHAO ,
  • Xiaodong MENG ,
  • Jianfei. ZHANG
Expand
  • Department of Urology,the 980th Hospital of the PLA Joint Logistics Support Force,Shijiazhuang 050000,Hebei,China

Received date: 2025-03-27

  Online published: 2025-07-29

Abstract

Objective To investigate the clinical characteristics of patients with chronic abacterial prostafitis (CAP),the CAP related factors were analyzed, and a risk prediction model for CAP were constructed and validated. Methods The clinical dataes of 252 suspected CAP patients admitted to the hospital from June 2022 to December 2024 were collected, the patients were divided into modeling set (n = 177) and validation set (n = 75) by 7∶3 ratio. Based on the modeling set dataes, the Lasso was used to screen CAP related predictive factors, a logistic multiple factor model was used to analyze the independent influence factors of CAP and a risk prediction model was constructed. The validation set patient dataes were used to plot ROC and DCA and validate the prediction model. Results There were 86 cases of CAP in the modeling set, accounting for 48.59%; 32 cases of CAP in the validation set, accounting for 42.67%. The Logistic multiple regression analysis showed that BMI, waist to hip ratio, abnormal elevation of IL-8, COX-2, and PGE2 in prostate fluid were independent influence factors of CAP (P < 0.05), a Nomogram column chart based on this was established.The ROC analysis showed that the sensitivity of the model for detecting CAP in the modeling and validation sets were 0.814 and 0.802, respectively, and the specificity were 0.673 and 0.703, respectively. The DCA analysis showed that the net benefit thresholds for modeling and validation sets by column charts are 0.1 ~ 0.9 and 0.2 ~ 1.0, respectively. Conclusions The occurrence of CAP is related to the patient's BMI, waist to hip ratio, the levels of IL-8, COX-2, and PGE2 in prostate fluid. The predictive model established based on this is highly accurate and it can help for CAP screening.

Cite this article

Yuhai QIAO , Chunhua DU , Xinhong ZHAO , Xiaodong MENG , Jianfei. ZHANG . Construction and validation of a risk prediction model for clinical characteristics of patients with chronic non⁃bacterial prostatitis[J]. The Journal of Practical Medicine, 2025 , 41(14) : 2224 -2230 . DOI: 10.3969/j.issn.1006-5725.2025.14.015

References

[1] 谈诚,杨欣. 与妇科泌尿系统症状相关的流行病学调查问卷[J]. 中国实用妇科与产科杂志,2017,33(10):995-999.
[2] 李保印,卜宏民,闫拥军,等. 几种方法治疗慢性细菌性前列腺炎疗效比较[J]. 河南大学学报(医学科学版), 2002,21(3):41-42.
[3] ABDEL-MEGUID T A, MOSLI H A, FARSI H,et al.Treatment of refractory category Ⅲ nonbacterial chronic prostatitis/chronic pelvic pain syndrome with intraprostatic injection of onabotulinumtoxinA: A prospective controlled study[J].Can J Urol, 2018,25(2):9273-9280.
[4] 李松,刘辉,张建华,等. 前列腺增生并发急性尿潴留的危险因素分析[J]. 河南大学学报(医学版),2022,41(6):449-452,458.
[5] 齐曼芳,黄高翔,周雪娟. 慢性非细菌性前列腺炎发病机制的研究进展[J]. 广西医科大学学报,2017,34(8):1247-1249.
[6] CHEN L D, WANG H, GE S D,et al. IL-6/STAT3 pathway is involved in the regulation of autophagy in chronic non-bacterial prostatitis cells, and may be affected by the NLRP3 inflammasome[J].Ultrastruct Pathol, 2021, 45(4-5):297-306. doi:10.1080/01913123.2021.1966149
[7] MYKONIATIS, I, PYRGIDIS, N, KALYVIANAKIS, D,et al.Comparing two different low-intensity shockwave therapy frequency protocols for nonbacterial chronic prostatitis/chronic pelvic pain syndrome: A two-arm, parallel-group randomized controlled trial[J]. Prostate, 2021, 81(9):499-507. doi:10.1002/pros.24119
[8] 梁朝朝,郝宗耀. 对慢性非细菌性前列腺炎的再认识[J]. 现代泌尿外科杂志,2019,24(6):425-428.
[9] MURPHY S F, SCHAEFFER A J, DONE J D, et al. Commensal bacterial modulation of thehost immune response to ameliorate pain in a murine model of chronic prostatitis[J]. Pain, 2017, 158(8):1517-1527. doi:10.1097/j.pain.0000000000000944
[10] 朱云海,许云飞,陈耀武,等. 高龄Ⅲ型前列腺炎患者血清和前列腺液中神经生长因子、炎性因子的表达水平及临床意义[J]. 现代生物医学进展,2018,18(2):272-275.
[11] LIU J, YU J, PENG X. Polysaccharides alleviates chronic nonbacterial prostatitis by preventing oxidative stress, regulating hormone production, modifying gut microbiota, and remodeling the DNA methylome[J]. J Agric Food Chem, 2020,68(45):12661-12670. doi:10.1021/acs.jafc.0c05943
[12] 赵建军,王立,陈鹏杰,等. 前列腺液中COX-2水平与慢性非细菌性前列腺炎症状的关系[J]. 细胞与分子免疫学杂志,2011,27(2):188-189.
[13] YUAN Z, LIU X, DENG W,et al.Correlation study of chronic nonbacterial prostatitis with the levels of COX-2 and PGE2 in prostatic secretion[J].Int Urol Nephrol, 2014, 46(10):1871-1875.
[14] 潘思源,张海博,杜春. 前列腺炎的临床诊断及治疗进展[J]. 中国临床研究,2022,35(3):404-409.
[15] 杨杰. Ⅲ型前列腺炎患者前列腺按摩液中NE,pH,IL-1β,TNF-α及PGE2的变化及其意义[J]. 临床与病理杂志,2018,38(12):2583-2588.
[16] 张世栋,苑炜,宋林超,等. 肥胖对慢性非细菌性前列腺炎大鼠前列腺IL-6和IL-8表达水平的影响[J]. 贵州医科大学学报,2017,42(10):1159-1163.
[17] NICKEL J C, FREEDLAND S J, CASTRO-SANTAMARIA R,et al.Chronic prostate inflammation predicts symptom progression in patients with chronic prostatitis/chronic pelvic pain[J].J Urol, 2017,198(1):122-128. doi:10.1016/j.juro.2017.01.035
[18] 唐昌亮,代时军,吴传勋,等. 肥胖对慢性无菌性前列腺炎发病的影响[J]. 现代医药卫生,2017,33(18):2842-2843.
[19] 蒋光昶,徐娟娟,韦贵武,等. 贵州省黔南地区农村居民前列腺疾病患病现状及危险因素[J]. 中国公共卫生,2019,35(7):818-823.
[20] 黄云龙,钟子涵. 前列舒通胶囊与左氧氟沙星联合治疗慢性细菌性前列腺炎疗效与安全性的Meta分析[J]. 中国医药指南,2025,23(3): 20-25.
[21] 罗恒,孙海波,李章春,等. 游泳运动联合药物干预对慢性非细菌性前列腺炎大鼠前列腺组织中Nrf2/ARE信号通路的影响[J]. 中国男科学杂志, 2025,39(1): 81-86,98.
[22] 李艳春, 崔伟锋. 温针灸联合济生肾气丸对肾阳不足型慢性非细菌性前列腺炎的影响[J]. 中医研究, 2024, 37 (12): 62-66.
[23] 陈慧,何启强,谢胜,等. 蛋白激酶C-α/Kelch样环氧氯丙烷相关蛋白1/核转录因子E2相关因子2/时核因子κB信号通路在慢性非细菌性前列腺炎小鼠中的表达及作用机制[J]. 陕西医学杂志,2024,53(10): 1320-1325.
[24] 姜涵中,孙立江. 慢性前列腺炎病人EPS中炎症相关生物标志物检测[J]. 青岛大学学报(医学版), 2023,59(3):397-400.
[25] 周萍,肖金海,江琼,等. 清热利湿通淋汤联合坦索罗辛治疗慢性前列腺炎湿热下注证的疗效[J]. 实用医学杂志, 2016,32(12): 2055-2057.
[26] 朱伟,田娟,何清湖,等. 电针对慢性非细菌性前列腺炎模型大鼠细胞因子TNF-α,IL-8,IL-10,β-EP的影响[J]. 临床心身疾病杂志,2016,22(z1):38-39.
[27] 代恒恒,李海松,宫僖浩,等. 通前络汤对慢性前列腺炎模型大鼠IL-2、IL-8及IgM水平的影响[J]. 中医学报,2020,35(10):2194-2196,2211.
[28] 陆良喜,史宏,黄志敏,等. TLR4/NF-κB-NLRP3炎症小体信号通路在实验性自身免疫性前列腺炎大鼠中的作用机制[J]. 实用医学杂志,2025,41(6):800-805.
[29] 王立,赵建军,陈鹏杰,等. 前列腺液中COX-2和PGE2与慢性非细菌性前列腺炎症状相关性研究[J]. 现代预防医学,2011,38(1):157-159.
[30] 陈力,付神波,屈喜梅,等. miR-211-5p对前列腺癌细胞放疗敏感性的影响及作用机制探讨[J]. 药物生物技术,2023,30(3):263-269.
Outlines

/